It has been observed that CTC detection can precede increases in blood PSA levels in men during recurrence of prostate cancer, thus monitoring CTCs could potentially lead to earlier implementation of effective intervention(s) to improve treatment outcome and overall survival [6,11]. This evidence concerns the gene KLK3 and prostate cancer.